Entia Biosciences launches supplement supporting kidney health
PORTLAND, Ore. — Entia Biosciences on Monday announced the launch of Ergo4Health/Kidney, a new nutritional supplement intended for individuals who are concerned about kidney health. The product comes in easy-to-swallow 500 mg capsules.
Ergo4Health/Kidney provides an essential amino acid L-ergothioneine ("Ergo"). Ergo is an antioxidant found only in food and is not created by the body. Research has further shown that Ergo is found in abundance in cells exposed to the highest amounts of oxidative stress such as the kidney, brain, liver, etc., where it is postulated to be needed most, noted Marvin Hausman, chief science and technology officer for Entia Biosciences.
Hausman had a scientific poster accepted for presentation at the National Kidney Foundation Meeting held during April 2017 in Orlando. The presentation highlighted the effect of Ergo4Health/Kidney on important kidney function bio-markers such as: eGFR (estimated Glomerular Filtration Rate), Creatinine and BUN (blood urea nitrogen).
Acura completes Nexafed transition to MainPointe with new formulation on horizon
PALATINE, Ill. — Acura Pharmaceuticals on Monday reported the completed transition of Nexafed and Nexafed Sinus to MainPointe Pharmaceuticals as that company commences selling activities with a new formulation coming to market soon.
"Consistent with our strategy to secure licensing partners to commercialize our product technologies, in March the company licensed Nexafed and Nexafed Sinus to MainPointe Pharmaceuticals and recorded license fee revenue of $2.5 million," Peter Clemens, SVP and CFO Acura, told analysts earlier this week. "We expect the sales to grow significantly over current levels as MainPointe brings their commercial expertise to bear to penetrate the pharmacy market."
MainPointe will be bringing to market Nexafed 2.0, added Bob Jones, Acura president and CEO. "We have completed manufacturing validation for Nexafed with our [microparticle] 2.0 formulation," he said. "The output from these batches has been transferred to MainPointe and is available for sale. We expect MainPointe will introduce Nexafed 2.0 to the market in this the third quarter."
"Conversion of pseudoephedrine products into methamphetamine remains an acute problem in many communities," John Schutte, MainPointe chairman and CEO, noted earlier this year in acquiring the rights to market Nexafed. "The Nexafed products have proven to be a success in curbing this costly problem and we look forward to driving this business forward."
Kline: Rx-to-OTC switch becoming more selective
PARSIPPANY, N.J. — Companies are being more selective in the Rx-to-OTC switches they pursue, Kline & Company reported in its latest research, the 13th study in its syndicated series, "Rx-to-OTC Switch Forecasts USA: Next Frontier."
According to Kline, future switches will depend on a combination of market-driven forces and safety, as determined by regulators. These switches will be characterized by the sponsor needing to overcome safety concerns with well-designed and well-executed trials that prove consumers can safely use the medication without the intervention of a healthcare professional.
Outlined in the Kline report, some of the categories with the greatest switch potential include benign prostatic hyperplasia, erectile dysfunction, migraine, overactive bladder and sleeping aids.